Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

223
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
223
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

186
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
186
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

296
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
296
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

404
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
404
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

292
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
292
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

24
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
24

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multimorbidity and the risk of post-tuberculosis lung disease: a systematic review and meta-analysis.

BMJ global health·2026
Same author

Renal Outcomes in People With HIV-1 and Renal Impairment Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide: Integrated Analysis From 9 Phase 3/3b Clinical Trials.

Open forum infectious diseases·2026
Same author

Optimizing metabolic management on integrase-based ART (OPTIMAR): study protocol for a 2 × 2 factorial, randomised, double-blind placebo-controlled trial to compare the addition of dapagliflozin versus placebo, and rosuvastatin plus ezetimibe versus pitavastatin, in people with HIV on integrase strand transfer inhibitor-based antiretroviral therapy with elevated metabolic risk.

Trials·2026
Same author

Prognostic value of ankle-brachial index and cardio-ankle vascular index for mortality and cardiovascular events in older people with HIV on long-term ART.

HIV medicine·2026
Same author

Rapid Review of Community Pharmacies and Potential for Expanded Access for the Treatment of HIV Infection and/or Tuberculosis in Sub-Saharan Africa.

The American journal of tropical medicine and hygiene·2026
Same author

Trends in frequency of HIV viral load and CD4 cell count monitoring among Asian cohort of adults with HIV: an analysis of the TREAT Asia HIV Observational Database, 2003-2018.

medRxiv : the preprint server for health sciences·2026

Related Experiment Video

Updated: Aug 9, 2025

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.7K

Treatment Strategy for Rifampin-Susceptible Tuberculosis.

Nicholas I Paton1, Christopher Cousins1, Celina Suresh1

  • 1From the Infectious Diseases Translational Research Programme and Yong Loo Lin School of Medicine, National University of Singapore (N.I.P., C.C., C.S., P.P.), National University Hospital (K.L.C.), and Singapore Clinical Research Institute (Q.L., S.L.L., Y.P.) - all in Singapore; the Faculty of Medicine, Universitas Indonesia, and Persahabatan General Hospital, Jakarta (E.B.), Dr. Soetomo Hospital, Surabaya (T.K.), Universitas Padjadjaran, Bandung (R.R.), Dr. Wahidin Sudirohusodo Hospital, Makassar (I.D.), and Saiful Anwar Hospital, Malang (J.J.R.S.) - all in Indonesia; De La Salle Medical and Health Sciences Institute, Cavite (V.B.D.), the Lung Centre of the Philippines, Quezon City (V.M.B.), and the Tropical Disease Foundation, Makati (R.S.V.) - all in the Philippines; the Infectious Diseases Institute, Makerere University, Kampala, Uganda (C.S.-W.); HIV-NAT, Thai Red Cross AIDS Research Center and Center of Excellence in Tuberculosis, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand (A.A.); the National Institute of TB and Respiratory Diseases, New Delhi, India (R.S.); and the London School of Hygiene and Tropical Medicine (N.I.P.) and the Medical Research Council Clinical Trials Unit at University College London (N.I.P., A.J.N., A.M.C.) - both in London.

The New England Journal of Medicine
|February 22, 2023
PubMed
Summary

A new 8-week bedaquiline-linezolid regimen for tuberculosis treatment proved noninferior to standard care. This shorter tuberculosis treatment strategy showed similar safety and clinical outcomes.

More Related Videos

Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test
08:10

Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test

Published on: April 9, 2012

80.9K
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

7.9K

Related Experiment Videos

Last Updated: Aug 9, 2025

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.7K
Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test
08:10

Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test

Published on: April 9, 2012

80.9K
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

7.9K

Area of Science:

  • Infectious Diseases
  • Clinical Trials
  • Pharmacology

Background:

  • Standard tuberculosis treatment involves a 6-month rifampin-based regimen.
  • The efficacy of shorter initial treatment strategies for tuberculosis is not well-established.

Purpose of the Study:

  • To evaluate a novel 8-week bedaquiline-linezolid regimen for tuberculosis treatment.
  • To compare the clinical outcomes and safety of the novel regimen against standard tuberculosis treatment.

Main Methods:

  • An adaptive, open-label, noninferiority trial was conducted.
  • Participants with rifampin-susceptible pulmonary tuberculosis were randomized to standard treatment or an 8-week regimen strategy.
  • The primary outcome was a composite of death, ongoing treatment, or active disease at 96 weeks.

Main Results:

  • The 8-week bedaquiline-linezolid strategy was noninferior to standard treatment (5.8% vs. 3.9% event rate).
  • The rifampin-linezolid strategy did not meet noninferiority criteria.
  • The bedaquiline-linezolid strategy resulted in a significantly shorter treatment duration (85 days vs. 180 days).
  • Adverse event rates were similar across groups.

Conclusions:

  • An 8-week bedaquiline-linezolid initial treatment strategy is a viable, noninferior alternative to standard tuberculosis therapy.
  • This novel regimen offers a shorter treatment duration without compromising safety or efficacy.
  • Further research may support shorter, effective tuberculosis treatment regimens.